Key result
Low-grade albuminuria is linked to ~39% higher composite cardiorenal risk.
Why the study?
Does low-grade (10-<30 mg/g) or clinically elevated (≥30 mg/g) albuminuria increase the risk of incident cardiovascular and renal outcomes in Chinese adults without baseline cardiorenal disease, and do healthy lifestyle and metabolic factors attenuate these risks?
Cohort (n=82,509)
Yes
Does low-grade (10-<30 mg/g) or clinically elevated (≥30 mg/g) albuminuria increase the risk of incident cardiovascular and renal outcomes in Chinese adults without baseline cardiorenal disease, and do healthy lifestyle and metabolic factors attenuate these risks?
Answers are grounded in this paper and cite their sources.
Cardiorenal risk begins to rise at low-grade albuminuria levels (UACR 10-30 mg/g) well below the traditional 30 mg/g guideline cutoff, representing a critical window where optimal lifestyle and metabolic management—particularly blood pressure control—can significantly attenuate future cardiovascular and renal events.
BACKGROUND: Albuminuria from low-grade to clinically elevated range confers cardiorenal risks. OBJECTIVES: The authors aimed to investigate the differential roles of lifestyle/metabolic factors in the association of fine-categorized and continuously measured urinary albumin-to-creatinine ratio (UACR) levels with cardiorenal outcomes. METHODS: A total of 82,509 participants from the China Cardiometabolic Disease and Cancer Cohort (4C) Study were included, with a median follow-up of 3.0 years. Outcomes included incident cardiovascular disease (CVD), incident CKD, their composite, along with surrogate markers. Lifestyle factors included tobacco use, alcohol use, diet, physical activity and sleep. Metabolic factors included diabetes, hypertension, abdominal obesity, and elevated low-density lipoprotein cholesterol. Cox proportional hazard models were used to calculate hazard ratios. Hypertension showed the largest relative contribution to cardiorenal risk, particularly in UACR <30 mg/g. CONCLUSIONS: Our findings highlighted low-grade albuminuria as a key preventive window for cardiorenal outcomes requiring both aspects of modifiable risk factors, and the cardiovascular benefits of metabolic improvement in established albuminuria.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) conducted a cohort in Low-grade to clinically elevated albuminuria and cardiovascular-renal risk (n=82,509). Low-grade albuminuria (UACR ≥10 to <30 mg/g) and clinically elevated albuminuria (UACR ≥30 mg/g), modified by lifestyle and metabolic health status vs. Normal urinary albumin-to-creatinine ratio (UACR <10 mg/g) was evaluated on Composite cardiorenal outcome (first occurrence of incident cardiovascular disease or incident chronic kidney disease) (HR 1.39, 95% CI 1.29-1.50). Low-grade albuminuria increased composite cardiorenal risk by 39% vs UACR </g, with risks attenuated by optimal lifestyle and metabolic health.
Synapse has enriched 10 related papers. Consider them for comparative context: